ArticleCell cycle (Georgetown, Tex.)2012
Independent transcriptional reprogramming and apoptosis induction by cisplatin.
Article in Cell cycle (Georgetown, Tex.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- GATOR1 complex controls cisplatin sensitivity.Cell death & disease · 2025Article
- Barleria extracts containing barlerin and verbascoside boost immunity and regulate CYP450 gene in prostate cancer.Scientific reports · 2025Article
- Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.International journal of molecular sciences · 2023Article
- RPRD1A stabilizes NRF2 and aggravates HCC progression through competing with p62 for TRIM21 binding.Cell death & disease · 2021Article
- Identification of new proteins related with cisplatin resistance in Saccharomyces cerevisiae.Applied microbiology and biotechnology · 2021Article
- New Platinum-Based Prodrug Pt(IV)Ac-POA: Antitumour Effects in Rat C6 Glioblastoma Cells.Neurotoxicity research · 2020Article
- Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.International journal of molecular sciences · 2019Article
- CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss.The Journal of experimental medicine · 2018Article
- Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach.International journal of molecular sciences · 2018Article
- Yeast Cells Exposed to Exogenous Palmitoleic Acid Either Adapt to Stress and Survive or Commit to Regulated Liponecrosis and Die.Oxidative medicine and cellular longevity · 2018Review
- Hesperidin from Citrus seed induces human hepatocellular carcinoma HepG2 cell apoptosis via both mitochondrial and death receptor pathways.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.Scientific reports · 2015Article
- Chemosensitizing and nephroprotective effect of resveratrol in cisplatin -treated animals.Cancer cell international · 2015Article
- Systems biology of cisplatin resistance: past, present and future.Cell death & disease · 2014Review
- Lipids and cell death in yeast.FEMS yeast research · 2014Review
- The cell death protease Kex1p is essential for hypochlorite-induced apoptosis in yeast.Cell cycle (Georgetown, Tex.) · 2013Article
- Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.Cell cycle (Georgetown, Tex.) · 2013Article
- Prognostic value of LIPC in non-small cell lung carcinoma.Cell cycle (Georgetown, Tex.) · 2013Article
- Immunosurveillance against tetraploidization-induced colon tumorigenesis.Cell cycle (Georgetown, Tex.) · 2013Article
- Vitamin B6 metabolism influences the intracellular accumulation of cisplatin.Cell cycle (Georgetown, Tex.) · 2013Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 7 institutions in 3 countries.
Funding
Abstract
Neither the molecular mechanisms whereby cancer cells intrinsically are or become resistant to the DNA-damaging agent cisplatin nor the signaling pathways that account for cisplatin cytotoxicity have thus far been characterized in detail. In an attempt to gain further insights into the molecular cascades elicited by cisplatin (leading to resistance or underpinning its antineoplastic properties), we comparatively investigated the ability of cisplatin, C2-ceramide and cadmium dichloride, alone or in the presence of an array of mitochondrion-protective agents, to trigger the permeabilization of purified mitochondria. In addition, we compared the transcriptional response triggered by cisplatin, C2-ceramide and cadmium dichloride in non-small cell lung carcinoma A549 cells. Finally, we assessed the capacity of cisplatin, C2-ceramide and cadmium dichloride to reduce the clonogenic potential of a battery of yeast strains lacking proteins involved in the regulation of cell death, DNA damage signaling and stress management. This multipronged experimental approach revealed that cisplatin elicits signaling pathways that are for the most part "private," i.e., that manifest limited overlap with the molecular cascades ignited by other inducers of mitochondrial apoptosis, and triggers apoptosis mainly in a transcription-independent fashion. Indeed, bona fide cisplatin-response modifiers that we have recently identified by a functional genome-wide siRNA screen are either not transcriptionally regulated during cisplatin-induced cell death or their transcriptional modulation reflects the activation of an adaptive response promoting cisplatin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.